Compare BHF & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHF | AMRX |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | N/A | 2018 |
| Metric | BHF | AMRX |
|---|---|---|
| Price | $62.61 | $12.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $57.71 | $15.60 |
| AVG Volume (30 Days) | 405.5K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | N/A |
| Revenue This Year | $27.10 | $4.48 |
| Revenue Next Year | $1.09 | $7.13 |
| P/E Ratio | ★ $4.34 | $58.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.16 | $7.02 |
| 52 Week High | $66.33 | $15.42 |
| Indicator | BHF | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.41 | 50.14 |
| Support Level | $59.04 | $12.45 |
| Resistance Level | $62.63 | $12.85 |
| Average True Range (ATR) | 0.54 | 0.48 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 94.13 | 29.84 |
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.